The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...

Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL ...

"Lymphopenia has long been recognized as a major driver and predictor of early mortality in cancer—yet until now, it has ...

Data from the ongoing Phase 2a study shows a 100% disease control rate with 45% of patients with advanced cutaneous T-cell lymphoma achieving an objective response:One complete response, three partial ...

The Global Medical Waste Management Market size is projected to be valued at USD 37.45 billion in 2024 and reach USD 59.42 ...

Data from the ongoing Phase 2a study shows a 100% disease control rate with 45% of patients with advanced cutaneous T-cell lymphoma achieving an objective response:One complete response, three partial ...

Dr. Jonathan Javitt, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals and Co-CEO of HOPE, will deliver a corporate presentation h ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

Lipid management for woman requires personalized care that considers sex-specific conditions across the reproductive lifespan ...

Robust responses observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior venetoclax, within efficacy-evaluable pivotal R/R mNPM1 AML population – – 60% (3/5) ...

Bank of America Corp DE reduced its stake in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) by 89.0% ...